Brain iron metabolism: Neurobiology and neurochemistry

Progress in Neurobiology

Volumn 83, Issue 3, 2007, Pages 149-173

  Ke, Ya ^a   Qian, Zhong Ming ^b,c  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c NANTONG UNIVERSITY   (China)

Author keywords

Aging; Brain iron metabolism; Brain iron misregulation; Iron regulatory protein; Iron release proteins; Iron storage proteins; Iron transport proteins; Iron uptake proteins; Neurodegenerative diseases

Indexed keywords

CERULOPLASMIN; FERRITIN; FERROPORTIN 1; HEME OXYGENASE 1; IRON; IRON REGULATORY FACTOR; IRON REGULATORY PROTEIN 2; LACTOFERRIN; MEMBRANE PROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PANTOTHENATE KINASE; POLYPEPTIDE; PROTEIN DERIVATIVE; PROTEIN HEPHAESTIN; STROMAL CELL DERIVED RECEPTOR 2; TRANSFERRIN; UNCLASSIFIED DRUG;

ACERULOPLASMINEMIA; AGING; APOPTOSIS; BLOOD CEREBROSPINAL FLUID BARRIER; DEGENERATIVE DISEASE; GENE MUTATION; GENETIC DISORDER; HALLERORDEN SPATZ SYNDROME; HEMOCHROMATOSIS; HEREDITY; HOMEOSTASIS; HUMAN; IRON KINETICS; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; MEDICAL ERROR; NEUROBIOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; HUMANS; IRON; NEUROBIOLOGY; NEUROCHEMISTRY;

EID: 34748899552     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2007.07.009     Document Type: Review

References (362)

1. Abboud S., and Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275 (2000) 19906-19912
2. Aguirre P., Mena N., Tapia V., Arredondo M., and Nunez M.T. Iron homeostasis in neuronal cells: a role for IREG1. BMC Neurosci. 6 1 (2005) 3
3. Aisen P., and Leibman A. Lactoferrin and transferrin: a comparative study. Biochim. Biophys. Acta 257 (1972) 314-323
4. Aisen P., Wessling-Resnick M., and Leibold E.A. Iron metabolism. Curr. Opin. Chem. Biol. 3 (1999) 200-206
5. Anderson B.F., Baker H.M., Norris G.E., Rice D.W., and Baker E.N. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2,8 A resolution. J. Mol. Biol. 209 (1989) 711-734
6. Andersen J.K. Iron dysregulation and Parkinson's disease. J. Alzheimer's Dis. 6 Suppl (2004) S47-S52
7. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 341 (1999) 1986-1995
8. Andrews N.C., Fleming M.D., and Gunshin H. Iron transport across biologic membranes. Nutr. Rev. 57 (1999) 114-123
9. Andrews N.C. Iron homeostasis: insights from genetics and animal models. Nat. Rev. Genet. 1 (2000) 208-217
10. Angelini L., Nardocci N., Rumi V., Zorzi C., Strada L., and Savoiardo M. Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J. Neurol. 239 (1992) 417-425
11. Aracena P., Aguirre P., Munoz P., and Nunez M.T. Iron and glutathione at the crossroad of redox metabolism in neurons. Biol. Res. 39 1 (2006) 157-165
12. Arredondo M., Munoz P., Mura C.V., and Nunez M.T. HFE inhibits apical iron uptake by intestinal epithelial (Caco-2) cells. FASEB J. 15 7 (2001) 1276-1278
13. Askwith C., Eide D., VanHo A., Bernard P.S., Li L., Davis-Kaplan S., Sipe D.M., and Kaplan J. The Fet3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake. Cell 76 (1994) 403-410
14. Askwith C.C., and Kaplan J. Site-directed mutagenesis of the yeast multicopper oxidase Fet3p. J. Biol. Chem. 273 (1998) 22415-22419
15. Atamna H. Heme, iron, and the mitochondrial decay of ageing. Ageing Res. Rev. 3 3 (2004) 303-318
16. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., and Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 274 (1999) 1116-1123
17. Baranano D.E., and Snyder S.H. Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10996-11002
18. Baranano D.E., Wolosker H., Bae B.I., Barrow R.K., Snyder S.H., and Ferris C.D. A mammalian iron ATPase induced by iron. J. Biol. Chem. 275 (2000) 15166-15173
19. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., and Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15 1 (1997) 29-35
20. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 25 1 (2004) 5-18
21. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., and Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1012 (2004) 224-236
22. Bartzokis G., Tishler T.A., Lu P.H., Villablanca P., Altshuler L.L., Carter M., Huang D., Edwards N., and Mintz J. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 28 3 (2007) 414-423
23. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., and Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79 (2001) 225-236
24. Berg D., Becker G., Riederer P., and Rieb O. Iron in neurodegenerative disorders. Neurotox. Res. 4 7-8 (2002) 637-653
25. Berg D. In vivo detection of iron and neuromelanin by transcranial sonography - a new approach for early detection of substantia nigra damage. J. Neural Transm. 113 (2006) 775-780
26. Berg D., Hochstrasser H., Schweitzer K.J., and Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox. Res. 9 1 (2006) 1-13
27. Beutler E. Hemochromatosis: genetics and pathophysiology. Annu. Rev. Med. 57 (2006) 331-347
28. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21 9 (2006) 1299-1310
29. Boll M.C., Sotelo J., Otero E., Alcaraz-Zubeldia M., and Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci. Lett. 265 (1999) 155-158
30. Bonkovsky H.L., Ponka P., Bacon B.R., Drysdale J., Grace N.D., and Tavill A.S. An update on iron metabolism: summary of the Fifth International Conference on Disorders of Iron Metabolism. Hepatology 24 (1996) 718-729
31. Bonn D. Pumping iron in Parkinson's disease. Lancet 347 (1996) 1614
32. Bradbury M.W. Transport of iron in the blood-brain-cerebrospinal fluid system. J. Neurochem. 69 (1997) 443-454
33. Brun A., and Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19 3 (1986) 253-262
34. Buchanan D.D., Silburn P.A., Chalk J.B., Le Couteur D.G., and Mellick G.D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 327 (2002) 91-94
35. Burdo J.R., Menzies S.L., Simpson I.A., Garrick L.M., Garrick M.D., Dolan K.G., Haile D.J., Beard J.L., and Connor J.R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66 (2001) 1198-1207
36. Burdo J.R., and Connor J.R. Brain iron uptake and homeostatic mechanisms: an overview. Biometals 16 (2003) 63-75
37. Burdo J.R., Antonetti D.A., Wolpert E.B., and Connor J.R. Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system. Neuroscience 121 4 (2003) 883-890
38. Burdo J.R., Simpson I.A., Menzies S., Beard J., and Connor J.R. Regulation of the profile of iron-management proteins in brain microvasculature. J. Cereb. Blood Flow Metab. 24 1 (2004) 67-74
39. Burn J., and Chinnery P.F. Neuroferritinopathy. Semin Pediatr. Neurol. 13 3 (2006) 176-181
40. Cairo G., and Pietrangelo A. Iron regulatory proteins in pathobiology. Biochem. J. 352 Pt 2 (2000) 241-250
41. Cairo G., Recalcati S., Pietrangelo A., and Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic. Biol. Med. 32 (2002) 1237-1243
42. Canonne-Hergaux F., Gruenheid S., Ponka P., and Gros P. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 93 (1999) 4406-4417
43. Canonne-Hergaux F., Zhang A.S., Ponka P., and Gros P. Characterization of the iron transporter DMT1 NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. Blood 98 (2001) 3823-3830
44. Canonne-Hergaux F., and Gros P. Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int. 62 1 (2002) 147-156
45. Casadesus G., Smith M.A., Zhu X., Aliev G., Cash A.D., Honda K., Petersen R.B., and Perry G. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J. Alzheimer's Dis. 6 2 (2004) 165-169
46. Cass W.A., Grondin R., Andersen A.H., Zhang Z., Hardy P.A., Hussey-Andersen L.K., Rayens W.S., Gerhardt G.A., and Gash D.M. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol. Aging 28 2 (2007) 258-271
47. Castellani R.J., Honda K., Zhu X., Cash A.D., Nunomura A., Perry G., and Smith M.A. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res. Rev. 3 3 (2004) 319-326
48. Chang Y.Z., Yuan Q.P., and Qian Z.M. Transferrin and transferrin receptor system and drug transport and delivery. Chinese Sci. Bull. 48 3 (2003) 213-218
49. Chang Y.Z., Duan S.L., and Qian Z.M. Transferrin receptor 2: current knowledge. Prog. Biophys. Biochem. 30 4 (2003) 533-536
50. Chang Y.Z., Qian Z.M., Wang K., Zhu L., Yang X.D., Du J.R., Ho K.P., Wang Q., and Ke Y. Effects of development and iron status on ceruloplasmin expression in rat brain. J. Cell Physiol. 204 2 (2005) 623-631
51. Chang Y.Z., Qian Z.M., Du J.R., Zhu L., Xu Yj, Li L.Z., Wang C.Y., Wang Q., Ge X.H., Ho K.P., Niu L.J., and Ke Y. Ceruloplasmin expression and its role in iron transport in C6 cells. Neurochem Int 50 5 (2007) 726-733
52. Chen H., Su T., Attieh Z.K., Fox T.C., McKie A.T., Anderson G.J., and Vulpe C.D. Systemic regulation of Hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 102 (2003) 1893-1899
53. Chen H., Attieh Z.K., Su T., Syed B.A., Gao H., Alaeddine R.M., Fox T.C., Usta J., Naylor C.E., Evans R.W., McKie A.T., Anderson G.J., and Vulpe C.D. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 103 (2004) 3933-3939
54. Ching K.H., Westaway S.K., Gitschier J., Higgins J.J., and Hayflick S.J. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 58 11 (2002) 1673-1674
55. Chinnery P.F., Curtis A.R., Fey C., Coulthard A., Crompton D., Curtis A., Lombes A., and Burn J. Neuroferritinopathy in a French family with late onset dominant dystonia. J. Med. Genet. 40 5 (2003) e69
56. Chowers I., Wong R., Dentchev T., Farkas R.H., Iacovelli J., Gunatilaka T.L., Medeiros N.E., Presley J.B., Campochiaro P.A., Curcio C.A., Dunaief J.L., and Zack D.J. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2135-2140
57. Cole G.M. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?. Neuron 37 6 (2003) 889-890
58. Connor J.R., Menzies S.L., St Martin S.M., and Mufson E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27 4 (1990) 595-611
59. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., and Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31 2 (1992) 327-335
60. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., and LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65 2 (1995) 717-724
61. Connor J.R., Pavlick G., Karli D., Menzies S.L., and Palmer C. A histochemical study of iron-positive cells in the developing rat brain. J. Comp. Neurol. 355 (1995) 111-123
62. Connor J.R., Menzies S.L., Burdo J.R., and Boyer P.J. Iron and iron management proteins in neurobiology. Pediatr. Neurol. 25 (2001) 118-129
63. Connor J.R., and Lee S.Y. HFE mutations and Alzheimer's disease. J. Alzheimer's Dis. 10 2-3 (2006) 267-276
64. Cooperman S.S., Meyron-Holtz E.G., Olivierre-Wilson H., Ghosh M.C., McConnell J.P., and Rouault T.A. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 106 (2005) 1084-1091
65. Costello D.J., Walsh S.L., Harrington H.J., and Walsh C.H. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J. Neurol. Neurosurg. Psychiatry 75 (2004) 631-633
66. Creagh A.L., Tiong J.W., Tian M.M., Haynes C.A., and Jefferies W.A. Calorimetric studies of melanotransferrin (p97) and its interaction with iron. J. Biol. Chem. 280 16 (2005) 15735-15741
67. Crompton D.E., Chinnery P.F., Fey C., Curtis A.R., Morris C.M., Kierstan J., Burt A., Young F., Coulthard A., Curtis A., Ince P.G., Bates D., Jackson M.J., and Burn J. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol. Dis. 29 3 (2002) 522-531
68. Crompton D.E., Chinnery P.F., Bates D., Walls T.J., Jackson M.J., Curtis A.J., and Burn J. Spectrum of movement disorders in neuroferritinopathy. Mov. Disord. 20 1 (2005) 95-99
69. Crowe A., and Morgan E.H. Iron and transferrin uptake by brain and cerebrospinal fluid in the rat. Brain Res. 592 (1992) 8-16
70. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28 (2001) 350-354
71. Davidson L.A., and Lonnerdal B. Fe-saturation and proteolysis of human lactoferrin: effect on brush-border receptor-mediated uptake of Fe and Mn. Am. J. Physiol. 257 (1989) G930-G934
72. Deane R., Zheng W., and Zlokovic B.V. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J. Neurochem. 88 4 (2004) 813-820
73. Deicher R., and Hörl W.H. New insights into the regulation of iron homeostasis. Eur. J. Clin. Invest. 36 (2006) 301-309
74. Dekker M.C., Giesbergen P.C., Njajou O.T., van Swieten J.C., Hofman A., Breteler M.M., and van Duijn C.M. Mutations in the hemochromatosis gene (HFE). Parkinson's disease and parkinsonism. Neurosci. Lett. 348 (2003) 117-119
75. di Patti M.C., Persichini T., Mazzone V., Polticelli F., Colasanti M., and Musci G. Interleukin-1beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci. Lett. 363 2 (2004) 182-186
76. Dickinson T.K., and Connor J.R. Immunohistochemical analysis of transferrin receptor: regional and cellular distribution in the hypotransferrinemic (hpx) mouse brain. Brain Res. 801 (1998) 171-181
77. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C., Lux S.E., Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J., Fleming M.D., Andrews N.C., and Zon L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403 (2000) 776-781
78. Doraiswamy P.M., and Finefrock A.E. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol. 3 7 (2004) 431-434
79. Double K.L., Maywald M., Schmittel M., Riederer P., and Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70 (1998) 2492-2499
80. Du X.L., Ke Y., Yuan L., Li R., Wang K., Ho K.P., and Qian Z.M. Apotransferrin is internalized and distributed same as holotransferrin in K562 cells. J. Cell Physiol. 201 (2004) 45-54
81. Egan R.A., Weleber R.G., Hogarth P., Gregory A., Coryell J., Westaway S., Gitschier J., Das S., and Hayflick S.J. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am. J. Ophthalmol. 140 (2005) 267-274
82. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20 (2000) 627-662
83. Erikson K.M., and Aschner M. Increased manganese uptake by primary astrocyte cultures with altered iron status is mediated primarily by divalent metal transporter. NeuroToxicology 27 (2006) 125-130
84. Espinosa de los Monteros A., Kumar S., Scully S., Cole R., and de Vellis J. Transferrin gene expression and secretion by rat brain cells in vitro. J. Neurosci. Res. 25 4 (1990) 576-580
85. Ewing J.F., and Maines M.D. Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not a heat shock protein. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 5364-5368
86. Fasano M., Bergamasco B., and Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J. Neurochem. 96 (2006) 909-916
87. Fasano M., Bergamasco B., and Lopiano L. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. J. Neural Transm. 113 (2006) 769-774
88. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., Hauw J.J., Agid Y., and Hirsch E.C. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9603-9607
89. Faucheux B.A., Bonnet A.M., Agid Y., and Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353 9157 (1999) 981-982
90. Ferreira C., Bucchini D., Martin M.E., Levi S., Arosio P., Grandchamp B., and Beaumont C. Early embryonic lethality of H ferritin gene deletion in mice. J. Biol. Chem. 275 (2000) 3021-3024
91. Ferris C.D., Jaffrey S.R., Sawa A., Takahashi M., Brady S.D., Barrow R.K., Tysoe S.A., Wolosker H., Baranano D.E., Dore S., Poss K.D., and Snyder S.H. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat. Cell Biol. 1 (1999) 152-157
92. Fillebeen C., Mitchell V., Dexter D., Benaissa M., Beauvillain J., Spik G., and Pierce A. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res. Mol. Brain Res. 72 (1999) 183-194
93. Fillebeen C., Descamps L., Dehouck M.P., Fenart L., Benaissa M., Spik G., Cecchelli R., and Pierce A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274 (1999) 7011-7017
94. Fillebeen C., Ruchoux M.M., Mitchell V., Vincent S., Benaissa M., and Pierce A. Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res. Mol. Brain Res. 96 (2001) 103-113
95. Fleming J., and Joshi J.G. Ferritin: isolation of aluminum-ferritin complex from brain. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7866-7870
96. Fleming M.D., Trenor III C.C., Su M.A., Foernzler D., Beier D.R., Dietrich W.F., and Andrews N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16 (1997) 383-386
97. Fleming M.D., Romano M.A., Su M.A., Garrick L.M., Garrick M.D., and Andrews N.C. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1148-1153
98. Fleming R.E., and Sly W.S. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8160-8162
99. Fleming R.E., and Sly W.S. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu. Rev. Physiol. 64 (2002) 663-680
100. Floris G., Medda R., Padiglia A., and Musci G. The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem. Pharmacol. 60 (2000) 1735-1741
101. Frankel D., Mehindate K., and Schipper H.M. Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia. J. Cell Physiol. 185 (2000) 80-86
102. Frazer D.M., Wilkins S.J., Becker E.M., Vulpe C.D., McKie A.T., Trinder D., and Anderson G.J. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 123 (2002) 835-844
103. Garrick M.D., Nunez M.T., Olivares M., and Harris E.D. Parallels and contrasts between iron and copper metabolism. Biometals 16 (2003) 1-8
104. Giometto B., Bozza F., Argentiero V., Gallo P., Pagni S., Piccinno M.G., and Tavolato B. Transferrin receptors in rat central nervous system. An immunocytochemical study. J. Neurosci. 98 1 (1990) 81-90
105. Giometto B., Taraloto B., and Graus F. Autoimmunity in paraneoplastic neurological syndromes. Brain Pathol. 9 (1999) 261-273
106. Gitlin J.D. Aceruloplasminemia. Pediatr Res. 44 (1998) 271-276
107. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur. J. Paediatr. Neurol. 6 5 (2002) 243-247
108. Graeber M.B., Raivich G., and Kreutzberg G.W. Increase of transferrin receptors and iron uptake in regenerating motor neurons. J. Neurosci. Res. 23 (1989) 342-345
109. Gregory A., and Hayflick S.J. Neurodegeneration with brain iron accumulation. Folia Neuropathol. 43 4 (2005) 286-296
110. Griffiths P.D., Dobson B.R., Jones G.R., and Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 Pt 4 (1999) 667-673
111. Griffiths W.J., and Cox T. Haemochromatosis: novel gene discovery and the molecular pathophysiology of iron metabolism. Hum. Mol. Genet. 9 (2000) 2377-2382
112. Griffiths W.J., Sly W.S., and Cox T.M. Intestinal iron uptake determined by divalent metal transporter is enhanced in HFE-deficient mice with hemochromatosis. Gastroenterology 120 6 (2001) 1420-1429
113. Grisoli M., Piperno A., Chiapparini L., Mariani R., and Savoiardo M. MR imaging of cerebral cortical involvement in aceruloplasminemia. Am. J. Neuroradiol. 26 3 (2005) 657-661
114. Gruenheid S., Cellier M., Vidal S., and Gros P. Identification and characterization of a second mouse Nramp gene. Genomics 25 (1995) 514-525
115. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., and Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 (1997) 482-488
116. Hahn P., Qian Y., Dentchev T., Chen L., Beard J., Harris Z.L., and Dunaief J.L. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13850-13855
117. Hallgren B., and Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3 1 (1958) 41-51
118. Hardy P.A., Gash D., Yokel R., Andersen A., Ai Y., and Zhang Z.M. Correlation of R2 With Total Iron Concentration in the Brains of Rhesus Monkeys. J. Magn. Reson. Imaging 21 (2005) 118-127
119. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., and Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2539-2543
120. Harris Z.L., Klomp L.W., and Gitlin J.D. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr. 67 (1998) 972S-977S
121. Harris Z.L., Durley A.P., Man T.K., and Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10812-10817
122. Harris Z.L., Davis-Kaplan S.R., Gitlin J.D., and Kaplan J. A fungal multicopper oxidase restores iron homeostasis in aceruloplasminemia. Blood 103 12 (2004) 4672-4673
123. Harrison P.M., and Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275 (1996) 161-203
124. Hartig M.B., Hortnagel K., Garavaglia B., Zorzi G., Kmiec T., Klopstock T., Rostasy K., Svetel M., Kostic V.S., Schuelke M., Botz E., Weindl A., Novakovic I., Nardocci N., Prokisch H., and Meitinger T. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann. Neurol. 59 2 (2006) 248-256
125. Hatanaka Y., Okano T., Oda K., Yamamoto K., and Yoshida K. Aceruloplasminemia with juvenile-onset diabetes mellitus caused by exon skipping in the ceruloplasmin gene. Intern. Med. 42 7 (2003) 599-604
126. Hayflick S.J., Penzien J.M., Michl W., Sharif U.M., Rosman N.P., and Wheeler P.G. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr. Neurol. 25 (2001) 166-169
127. Hayflick S.J. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr. Opin. Pediatr. 15 6 (2003) 572-577
128. Hayflick S.J., Westaway S.K., Levinson B., Zhou B., Johnson M.A., Ching K.H., and Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N. Engl. J. Med. 348 1 (2003) 33-40
129. Hayflick S.J. Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin. Pediatr. Neurol. 13 3 (2006) 182-185
130. He Y., Thong P.S., Lee T., Leong S.K., Mao B.Y., Dong F., and Watt F. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic. Biol. Med. 35 5 (2003) 540-547
131. Heafield M.T., Fearn S., Steventon G.B., Waring R.H., Williams A.C., and Sturman S.G. Plasma cysteine and sulphate levels in patients with motor neurone. Parkinson's and Alzheimer's disease. Neurosci. Lett. 110 (1990) 216-220
132. Hellman N.E., Schaefer M., Gehrke S., Stegen P., Hoffman W.J., Gitlin J.D., and Stremmel W. Hepatic iron overload in aceruloplasminaemia. Gut 47 (2000) 858-860
133. Hellman N.E., and Gitlin J.D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 22 (2002) 439-458
134. Hellman N.E., Kono S., Miyajima H., and Gitlin J.D. Biochemical analysis of a missense mutation in aceruloplasminemia. J. Biol. Chem. 277 (2002) 1375-1380
135. Hentze M.W., and Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8175-8182
136. Ho K.P., Xiao D.S., Ke Y., and Qian Z.M. The decreased activity of cytosolic aconitase in the liver, spleen and bone marrow in the exercised rats. Biochem. Biophys. Res. Comm. 282 1 (2001) 264-267
137. Hochstrasser H., Tomiuk J., Walter U., Behnke S., Spiegel J., Krüger R., Becker G., Riess O., and Berg D. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J. 19 13 (2005) 1851-1853
138. Hoepken H.H., Korten T., Robinson S.R., and Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 88 (2004) 1194-1202
139. Hortnagel K., Prokisch H., and Meitinger T. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum. Mol. Genet. 12 3 (2003) 321-327
140. Hu J., and Connor J.R. Demonstration and characterization of the iron regulatory protein in human brain. J. Neurochem. 67 (1996) 838-844
141. Huang E., Ong W.Y., and Connor J.R. Distribution of divalent metal transporter-1 in the monkey basal ganglia. Neuroscience 128 3 (2004) 487-496
142. Huang E., Ong W.Y., Go M.L., and Connor J.R. Upregulation of iron regulatory proteins and divalent metal transporter-1 isoforms in the rat hippocampus after kainate induced neuronal injury. Exp. Brain Res. 170 (2006) 376-386
143. Huang Y., Wu L., Xu C., Yang B., and Wang R. Increased HO-1 expression and decreased iNOS expression in the hippocampus from adult spontaneously hypertensive rats. Cell Biochem. Biophys. 46 1 (2006) 35-42
144. Hubert N., and Hentze M.W. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12345-12350
145. Hugman A. Hepcidin: an important new regulator of iron homeostasis. Clin. Lab. Haem. 28 (2006) 75-83
146. Hulet S.W., Hess E.J., Debinski W., Arosio P., Bruce K., Powers S., and Connor J.R. Characterization and distribution of ferritin binding sites in the adult mouse brain. J. Neurochem. 72 (1999) 868-874
147. Hulet S.W., Powers S., and Connor J.R. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J. Neurol. Sci. 165 (1999) 48-55
148. Hulet S.W., Heyliger S.O., Powers S., and Connor J.R. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J. Neurosci. Res. 61 (2000) 52-60
149. Jefferies W.A., Food M.R., Gabathuler R., Rothenberger S., Yamada T., Yasuhara O., and McGeer P.L. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 712 (1996) 122-126
150. Jefferies W.A., Dickstein D.L., and Ujiie M. Assessing p97 as an Alzheimer's disease serum biomarker. J. Alzheimer's Dis. 3 3 (2001) 339-344
151. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., and Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park Dis. Dement. Sect. 2 4 (1990) 327-340
152. Jellinger K., Linert L., Kienzl E., Herlinger E., and Youdim M.B. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 46 Suppl. (1995) 297-314
153. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14 (1999) 115-140
154. Jellinger K.A. Neuropathological spectrum of synucleinopathies. Mov. Disord. 6 Suppl (2003) S2-S12
155. Jeong S.Y., and David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278 (2003) 27144-27148
156. Ji B., Maeda J., Higuchi M., Inoue K., Akita H., Harashima H., and Suhara T. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 78 (2006) 851-855
157. Jiang D.H., Ke Y., Cheng Y.Z., Ho K.P., and Qian Z.M. Distribution of ferroportin1 protein in different regions of developing rat brain. Dev. Neurosci. 24 (2002) 94-98
158. Johnson M.A., Kuo Y.M., Westaway S.K., Parker S.M., Ching K.H., Gitschier J., and Hayflick S.J. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann. N. Y. Acad. Sci. 1012 (2004) 282-298
159. Kaplan J., and O'Halloran T.V. Iron metabolism in eukaryotes: Mars and Venus at it again. Science 271 (1996) 1510-1512
160. Kaplan J., and Kushner J.P. Mining the genome for iron. Nature 403 (2000) 711-713
161. Kato J., Fujikawa K., Kanda M., Fukuda N., Sasaki K., Takayama T., Kobune M., Takada K., Takimoto R., Hamada H., Ikeda T., and Niitsu Y. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am. J. Hum. Genet. 69 (2001) 191-197
162. Kaur D., and Andersen J.K. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?. Aging Cell 1 1 (2002) 17-21
163. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 6 (2003) 899-909
164. Kaur D., and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res. Rev. 3 3 (2004) 327-343
165. Kawamata T., Tooyama I., Yamada T., Walker D.G., and McGeer P.L. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am. J. Pathol. 142 (1993) 1574-1585
166. Kawanami T., Kato T., Daimon M., Tominaga M., Sasaki H., Maeda K., Arai S., Shikama Y., and Katagiri T. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J. Neurol. Neurosurg. Psychiatry 61 (1996) 506-509
167. Ke Y., and Qian Z.M. DMT1: a newly discovered mammalian iron transport protein. Prog. Biophys. Biochem. 29 2 (2002) 2-6
168. Ke Y., Chen Y.Y., Chang Y.Z., Duan X.L., Ho K.P., Jiang D.H., Wang K., and Qian Z.M. Post-transcriptional expression of DMT1 in the heart of rat. J. Cell Physiol. 196 (2003) 124-130
169. Ke Y., and Qian Z.M. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2 (2003) 246-253
170. Ke Y., Chang Y.Z., Duan X.L., Du J.R., Zhu L., Wang K., Yang X.D., Ho K.P., and Qian Z.M. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol. Aging. 26 (2005) 739-748
171. Ke Y., Ho K.P., Du J.R., Zhu L., Xu Y.J., Wang Q., Wang C.Y., Li L.Z., Ge X.H., Chang Y.Z., and Qian Z.M. Role of soluble ceruloplasmin on iron uptake by midbrain and hippocampus neurons. J. Cell Biochem. 98 4 (2006) 912-919
172. Kelner G.S., Lee M., Clark M.E., Maciejewski D., McGrath D., Rabizadeh S., Lyons T., Bredesen D., Jenner P., and Maki R.A. The copper transport protein Atox1 promotes neuronal survival. J. Biol. Chem. 275 (2000) 580-584
173. Kennard M.L., Feldman H., Yamada T., and Jefferies W.A. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat. Med. 2 (1996) 1230-1235
174. Kim D.K., Seo M.Y., Lim S.W., Kim S., Kim J.W., Carroll B.J., Kwon D.Y., Kwon T., and Kang S.S. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology 25 (2001) 84-90
175. Klausner R.D., Rouault T.A., and Harford J.B. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72 (1993) 19-28
176. Klomp L.W., and Gitlin J.D. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5 (1996) 1989-1996
177. Klomp L.W., Farhangrazi Z.S., Dugan L.L., and Gitlin J.D. Ceruloplasmin gene expression in the murine central nervous system. J. Clin. Invest. 98 (1996) 207-215
178. Knutson M.D., Oukka M., Koss L.M., Aydemir F., and Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc. Natl. Acad. Sci. U.S.A. 102 5 (2005) 1324-1328
179. Koeppen A.H. The history of iron in the brain. J. Neurol. Sci. 134 Suppl (1995) 1-9
180. Kotzbauer P.T., Truax A.C., Trojanowski J.Q., and Lee V.M. Altered neuronal mitochondrial coenzyme a synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J. Neurosci. 25 3 (2005) 689-698
181. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., and Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480 (2000) 147-150
182. Lambert L.A., Perri H., and Meehan T.J. Evolution of duplications in the transferrin family of proteins. Comp. Biochem. Physiol. Part B 140 (2005) 11-25
183. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Tsokos M., Switzer R., 3rd, Grinberg A., Love P., Tresser N., and Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27 (2001) 209-214
184. Lee D.W., Andersen J.K., and Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol. Interv. 6 2 (2006) 89-97
185. Lee P.L., Gelbart T., West C., Halloran C., and Beutler E. The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms. Blood Cells Mol. Dis. 24 (1998) 199-215
186. Lee S.Y., and Connor J.R. Regulation of Hfe by stress factors in BV-2 cells. Neurobiol. Aging 26 6 (2005) 803-812
187. Levenson C.W., and Fitch C.A. Effect of altered thyroid hormone status on rat brain ferritin H and ferritin L mRNA during postnatal development. Brain Res. Dev. Brain Res. 119 1 (2000) 105-109
188. Levenson C.W., and Tassabehji N.M. Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res. Rev. 3 3 (2004) 251-263
189. Leveugle B., Spik G., Perl D.P., Bouras C., Fillit H.M., and Hof P.R. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 650 (1994) 20-31
190. Leveugle B., Faucheux B.A., Bouras C., Nillesse N., Spik G., Hirsch E.C., Agid Y., and Hof P.R. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol. (Berl.) 91 (1996) 566-572
191. Levi S., Cozzi A., and Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract. Res. Clin. Haematol. 18 2 (2005) 265-276
192. Levy J.E., Montross L.K., and Andrews N.C. Genes that modify the hemochromatosis phenotype in mice. J. Clin. Invest. 105 (2000) 1209-1216
193. Li H.Y., and Qina Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22 3 (2002) 225-250
194. Li H.Y., Sun H.Z., and Qian Z.M. Drug delivery and targeting: role of transferrin/transferrin receptor system. Trend Pharmacol. Sci. 23 5 (2002) 206-209
195. Li H.Y., Sun H.Z., and Qian Z.M. Membrane-inserted conformation of transmembrane domain 4 of divalent metal transporter. Biochem J. 372 Pt 3 (2003) 757-766
196. Lis A., Barone T.A., Paradkar P.N., Plunkett R.J., and Roth J.A. Expression and localization of different forms of DMT1 in normal and tumor astroglial cells. Brain Res. Mol. Brain Res. 122 1 (2004) 62-70
197. Liu G., Garrett M.R., Men P., Zhu X., Perry G., and Smith M.A. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta 1741 3 (2005) 246-252
198. Logan J.I. Hereditary deficiency of ferroxidase (aka caeruloplasmin). J. Neurol. Neurosurg. Psychiatry 61 (1996) 431-432
199. Maciel P., Cruz V.T., Constante M., Iniesta I., Costa M.C., Gallati S., Sousa N., Sequeiros J., Coutinho P., and Santos M.M. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 65 4 (2005) 603-605
200. Malecki E.A., Devenyi A.G., Beard J.L., and Connor J.R. Existing and emerging mechanisms for transport of iron and manganese to the brain. J. Neurosci. Res. 56 (1999) 113-122
201. Mancuso M., Davidzon G., Kurlan R.M., Tawil R., Bonilla E., Di Mauro S., and Powers J.M. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 64 4 (2005) 280-294
202. Manis J. Intestinal iron-transport defect in the mouse with sex-linked anemia. Am J. Physiol. 220 (1971) 135-139
203. Martin W.R., Ye F.Q., and Allen P.S. Increasing striatal iron content associated with normal aging. Mov. Disord. 13 2 (1998) 281-286
204. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell. 5 (2000) 299-309
205. McKie A.T., Barrow D., Latunde-Dada G.O., Rolfs A., Sager G., Mudaly E., Mudaly M., Richardson C., Barlow D., Bomford A., Peters T.J., Raja K.B., Shirali S., Hediger M.A., Farzaneh F., and Simpson R.J. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291 (2001) 1755-1759
206. Meyron-Holtz E.G., Ghosh M.C., and Rouault T.A. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306 5704 (2004) 2087-2090
207. Mims M.P., and Prchal J.T. Divalent metal transporter 1. Hematology 10 4 (2005) 339-345
208. Min K., Yang M., Kim S.U., Jou I., and Joe E. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J. Neurosci. 26 6 (2006) 1880-1887
209. Mir P., Edwards M.J., Curtis A.R., Bhatia K.P., and Quinn N.P. Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. Mov. Disord. 20 2 (2005) 243-245
210. Miyajima H., Nishimura Y., Mizoguchi K., Sakamoto M., Shimizu T., and Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 37 (1987) 761-767
211. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., and Gitlin J.D. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann. Neurol. 41 (1997) 404-407
212. Miyajima H., Fujimoto M., Kohno S., Kaneko E., and Gitlin J.D. CSF abnormalities in patients with aceruloplasminemia. Neurology 51 (1998) 1188-1190
213. Miyajima H., Kohno S., Takahashi Y., Yonekawa O., and Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 53 (1999) 617-619
214. Miyajima H., Adachi J., Kohno S., Takahashi Y., Ueno Y., and Naito T. Increased oxysterols associated with iron accumulation in the brains and visceral organs of acaeruloplasminaemia patients. QJM 94 (2001) 417-422
215. Miyajima H., Takahashi Y., Kono S., Sugimoto M., Suzuki Y., Hishida A., Sakamoto M., and Ouchi Y. Glucose and oxygen hypometabolism in aceruloplasminemia brains. Intern. Med. 41 (2002) 186-190
216. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 23 (2003) 345-350
217. Moalem S., Percy M.E., Andrews D.F., Kruck T.P., Wong S., Dalton A.J., Mehta P., Fedor B., and Warren A.C. Are hereditary hemochromatosis mutations involved in Alzheimer disease?. Am J. Med. Genet. 93 (2000) 58-66
218. Mollgard K., Dziegielewska K.M., Saunders N.R., Zakut H., and Soreq H. Synthesis and location of plasma proteins in the developing human brain, Integrity of the fetal blood-brain barrier to endogenous proteins of hepatic origin. Dev. Biol. 128 (1988) 207-221
219. Moos T. Increased accumulation of transferrin by motor neurons of the mouse mutant progressive motor neuronopathy (pmn/pmn). J. Neurocytol. 24 (1995) 389-398
220. Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J. Comp. Neurol. 375 (1996) 675-692
221. Moos T. Brain iron homeostasis. Dan. Med. Bull. 49 (2002) 279-301
222. Moos T., and Morgan E.H. Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid. J. Neurosci. Res. 54 (1998) 486-494
223. Moos T., and Morgan E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol. Neurobiol. 20 1 (2000) 77-95
224. Moos T., and Morgan E.H. A morphological study of the developmentally regulated transport of iron into the brain. Dev. Neurosci. 24 2-3 (2002) 99-105
225. Moos T., and Morgan E.H. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann. N. Y. Acad. Sci. 1012 (2004) 14-26
226. Moos T., and Morgan E.H. The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J. Neurochem. 88 (2004) 233-245
227. Moos T., and Rosengren Nielsen T. Ferroportin in the postnatal rat brain: implications for axonal transport and neuronal export of iron. Semin. Pediatr. Neurol. 13 3 (2006) 149-157
228. Morgan E.H., and Moos T. Mechanism and developmental changes in iron transport across the blood-brain barrier. Dev. Neurosci. 24 2-3 (2002) 106-113
229. Morita T., Mizutani Y., Sawada M., and Shimada A. Immunohistochemical and ultrastructural findings related to the blood-brain barrier in the blood vessels of the cerebral white matter in aged dogs. J. Comp. Path. 133 (2005) 14-22
230. Moroo I., Ujiie M., Walker B.L., Tiong J.W., Vitalis T.Z., Karkan D., Gabathuler R., Moise A.R., and Jefferies W.A. Identification of a novel route of iron transcytosis across the mammalian blood-brain barrier. Microcirculation 10 (2003) 457-462
231. Mukhopadhyay C.K., Attieh Z.K., and Fox P.L. Role of ceruloplasmin in cellular iron uptake. Science 279 (1998) 714-717
232. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalisation. Science 306 (2004) 2090-2093
233. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., and Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8780-8785
234. Nicolas G., Viatte L., Bennoun M., Beaumont C., Kahn A., and Vaulont S. Hepcidin a new iron regulatory peptide. Blood Cells Mol. Dis. 29 (2002) 327-335
235. Nielsen J.E., Jensen L.N., and Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psychiatry 59 (1995) 318-321
236. Nunez-Millacura C., Tapia V., Munoz P., Maccioni R.B., and Nunez M.T. An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J. Neurochem. 82 (2002) 240-248
237. Ogg R.J., Langston J.W., Haacke E.M., Steen R.G., and Taylor J.S. The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn. Reson Imaging 17 8 (1999) 1141-1148
238. Oide T., Yoshida K., Kaneko K., Ohta M., and Arima K. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol. Appl. Neurobiol. 32 2 (2006) 170-176
239. Ong W.Y., and Farooqui A.A. Iron, neuroinflammation, and Alzheimer's disease. J. Alzheimer's Dis. 8 2 (2005) 183-200
240. Osaki S., Johnson D.A., and Frieden E. The possible role of the ferrous oxidase activity of ceruloplasmin in normal human serum. J. Biol. Chem. 241 (1966) 11490-11491
241. Oshiro S., Kawahara M., Kuroda Y., Zhang C., Cai Y., Kitajima S., and Shirao M. Glial cells contribute more to iron and aluminum accumulation but are more resistant to oxidative stress than neuronal cells. Biochim. Biophys. Acta 1502 (2000) 405-414
242. Palomo T., Beninger R.J., Kostrzewa R.M., and Archer T. Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations. Neurotox. Res. 5 1-2 (2003) 1-26
243. Papanikolaou G., Samuels M.E., Ludwig E.H., MacDonald M.L., Franchini P.L., Dube M.P., Andres L., MacFarlane J., Sakellaropoulos N., Politou M., Nemeth E., Thompson J., Risler J.K., Zaborowska C., Babakaiff R., Radomski C.C., Pape T.D., Davidas O., Christakis J., Brissot P., Lockitch G., Ganz T., Hayden M.R., and Goldberg Y.P. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet. 36 (2004) 77-82
244. Paradkar P.N., and Roth J.A. Nitric oxide transcriptionally down-regulates specific isoforms of divalent metal transporter (DMT1) via NF-kappaB. J. Neurochem. 96 6 (2006) 1768-1777
245. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276 (2001) 7806-7810
246. Patel B.N., and David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J. Biol. Chem. 272 (1997) 20185-20190
247. Patel B.N., Dunn R.J., and David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J. Biol. Chem. 275 (2000) 4305-4310
248. Pellecchia M.T., Valente E.M., Cif L., Salvi S., Albanese A., Scarano V., Bonuccelli U., Bentivoglio A.R., D'Amico A., Marelli C., Di Giorgio A., Coubes P., Barone P., and Dallapiccola B. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 64 10 (2005) 1810-1812
249. Perry T.L., Norman M.G., Yong V.W., Whiting S., Crichton J.U., Hansen S., and Kish S.J. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann. Neurol. 18 (1985) 482-489
250. Petrak J., and Vyoral D. Hephaestin-a ferroxidase of cellular iron export. Int. J. Biochem. Cell Biol. 37 6 (2005) 1173-1178
251. Pietrangelo A. The ferroportin disease. Blood Cells Mol. Dis. 32 (2004) 131-138
252. Pinero D.J., Hu J., Cook B.M., Scaduto Jr. R.C., and Connor J.R. Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool. Biochim. Biophys. Acta 1497 (2000) 279-288
253. Ponting C.P. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?. Hum. Mol. Genet. 10 (2001) 1853-1858
254. Pulliam J.F., Jennings C.D., Kryscio R.J., Davis D.G., Wilson D., Montine T.J., Schmitt F.A., and Markesbery W.R. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119 (2003) 48-53
255. Qian Z.M., and Morgan E.H. Effect of lead on the transport of transferrin-free and transferrin-bound iron into rabbit reticulocytes. Biochem. Pharmacol. 40 5 (1990) 1049-1054
256. Qian Z.M., and Morgan E.H. Effect of metabolic inhibitors on uptake of transferrin-free iron by reticulocytes. Biochim. Biophys. Acta 1073 (1991) 456-462
257. Qian Z.M., and Morgan E.H. Changes in transferrin-free and transferrin-bound iron uptake by cells during reticulocyte maturation in vivo and in vitro. Biochim. Biophys. Acta 1135 (1992) 87-89
258. Qian Z.M., and Tang P.L. Mechanisms of iron uptake by mammalian cells. Biochim. Biophys. Acta 1269 (1995) 205-214
259. Qian Z.M., Tang P.L., and Morgan E.H. Effect of lipid peroxidation on transferrin-free iron uptake by rabbit reticulocytes. Biochim. Biophys. Acta 1310 (1996) 293-302
260. Qian Z.M., Wang Q., and Pu Y.M. Brain iron and neurological disorders. Chinese Med. J. 110 6 (1997) 455-458
261. Qian Z.M., Tang P.L., and Wang Q. Iron crosses the endosomal membrane by a carrier-mediated process. Prog. Biophys. Mol. Biol. 67 1 (1997) 1-15
262. Qian Z.M., and Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res. Brain Res. Rev. 27 (1998) 257-267
263. Qian Z.M., Pu Y.M., Tang P.L., and Wang Q. Transferrin-bound iron uptake by the cultured cerebellar granule cells. Neurosci. Lett. 251 1 (1998) 9-12
264. Qian Z.M., Pu Y.M., Wang Q., Ke Y., Chen W.F., Shen X., Feng Y.M., and Tang P.L. Cerebellar granule cells acquire transferrin-free iron by a carrier-mediated process. Neuroscience 92 (1999) 577-582
265. Qian Z.M., To Y., and Feng Y.M. Transferrin receptor on the plasma membrane of cultured rat astrocytes. Exp. Brain Res. 129 3 (1999) 473-476
266. Qian Z.M., Liao Q.K., To Y., Ke Y., Tsoi Y.K., Wang G.F., and Ko K.P. Transferrin-bound and transferrin-free iron uptake by the cultured brain astrocytes. Cell Mol. Biol. 46 3 (2000) 541-548
267. Qian Z.M., and Shen X. Brain iron transport and neurodegeneration. Trends Mol. Med. 7 (2001) 103-108
268. Qian Z.M., Tsoi Y.K., Ke Y., and Wong M.S. Ceruloplasmin promotes iron uptake rather than release in BT325 cells. Exp. Brain Res. 140 (2001) 369-374
269. Qian Z.M., and Ke Y. Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res. Brain Res. Rev. 35 (2001) 287-294
270. Qian Z.M. Nitric oxide and changes of iron metabolism in exercise. Biol. Rev. 77 (2002) 529-536
271. Qian Z.M., Li H., and Sun H. Ho K: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
272. Qian Z.M., Chang Y.Z., Du J.R., Ho K.P., Zhu L., Xu Y.J., Li L.Z., Wang C.Y., Wang Q., Ge X.H., Niu L.J., Lin L., Ke Y. (2007). Development and iron-dependent expression hephaestin of in different brain regions of rats. J. Cell Biochem., May 21; [Epub ahead of print].
273. Quintana C., Bellefqih S., Laval J.Y., Guerquin-Kern J.L., Wu T.D., Avila J., Ferrer I., Arranz R., and Patino C. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 153 (2006) 42-54
274. Racette B.A., Perry A., D'Avossa G., and Perlmutter J.S. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. Mov. Disord. 16 6 (2001) 1148-1152
275. Rebeck G.W., Harr S.D., Strickland D.K., and Hyman B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann. Neurol. 37 (1995) 211-217
276. Reif D.W. Ferritin as a source of iron for oxidative damage. Free Radic. Biol. Med. 12 (1992) 417-427
277. Reilly C.A., and Aust S.D. Stimulation of the ferroxidase activity of ceruloplasmin during iron loading into ferritin. Arch Biochem. Biophys. 347 (1997) 242-248
278. Richardson D.R. Role of ceruloplasmin and ascorbate in cellular iron release. J. Lab Clin. Med. 134 (1999) 454-465
279. Richardson D.R. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur. J. Biochem. 267 (2000) 1290-1298
280. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci. 1012 (2004) 326-341
281. Richardson D.R., and Morgan E.H. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta 1690 2 (2004) 124-133
282. Roskams A.J., and Connor J.R. Transferrin receptor expression in myelin deficient (md) rats. J. Neurosci Res. 31 (1992) 421-427
283. Roth J.A., Horbinski C., Feng L., Dolan K.G., Higgins D., and Garrick M.D. Differential localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells. J. Neurosci. 20 (2000) 7595-7601
284. Rothenberger S., Food M.R., Gabathuler R., Kennard M.L., Yamada T., Yasuhara O., McGeer P.L., and Jefferies W.A. Coincident expression and distribution of melanotransferrin and transferring receptor in human brain capillary endothelium. Brain Res. 712 (1996) 117-121
285. Rouault T.A. Systemic iron metabolism: a review and implications for brain iron metabolism. Pediatr. Neurol. 25 (2001) 130-137
286. Rouault T.A., and Cooperman S. Brain iron metabolism. Semin. Pediatr. Neurol. 13 3 (2006) 142-148
287. Roy C.N., and Andrews N.C. Recent advances in disorders of iron metabolism: mutations, mechanisms and modifiers. Hum. Mol. Genet. 10 (2001) 2181-2186
288. Roy C.N., Blemings K.P., Deck K.M., Davies P.S., Anderson E.L., Eisenstein R.S., and Enns C.A. Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells. J. Cell Physiol. 190 (2002) 218-226
289. Rump P., Lemmink H.H., Verschuuren-Bemelmans C.C., Grootscholten P.M., Fock J.M., Hayflick S.J., Westaway S.K., Vos Y.J., and van Essen A.J. A novel 3-bp deletion in the PANK2 gene of Dutch patients with pantothenate kinase-associated neurodegeneration: evidence for a founder effect. Neurogenetics 6 (2005) 201-207
290. Russo N., Edwards M., Andrews T., O'Brien M., and Bhatia K.P. Hereditary haemochromatosis is unlikely to cause movement disorders-a critical review. J. Neurol. 251 7 (2004) 849-852
291. Sadrzadeh S.M., and Saffari Y. Iron and brain disorders. Am. J. Clin. Pathol. 121 Suppl (2004) S64-S70
292. Saleheen D., Nazir A., Khanum S., Haider S.R., and Frossard P. A novel mutation in a patient with pantothenate kinase-associated neurodegeneration. JAMC 173 6 (2005) 578-579
293. Salzer J.L., Lovejoy L., Linder M.C., and Rosen C. Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin. J. Neurosci. Res. 54 (1998) 147-157
294. Sampietro M., Caputo L., Casatta A., Meregalli M., Pellagatti A., Tagliabue J., Annoni G., and Vergani C. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Aging 22 (2001) 563-568
295. Sayre L.M., Perry G., and Smith M.A. In situ methods for detection and localization of markers of oxidative stress: application in neurodegenerative disorders. Methods Enzymol. 309 (1999) 133-152
296. Schipper H.M. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. Neurotox. Res.. 1 (1999) 57-70
297. Schipper H.M., Bernier L., Mehindate K., and Frankel D. Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. J. Neurochem. 72 (1999) 1802-1811
298. Schipper H.M. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol. 35 (2000) 821-830
299. Schipper H.M. Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress. Ann. N. Y. Acad. Sci. 1012 (2004) 84-93
300. Schipper H.M. Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med. 37 (2004) 1995-2011
301. Schipper H.M. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res. Rev. 3 (2004) 265-301
302. Schipper H.M., Bennett D.A., Liberman A., Bienias J.L., Schneider J.A., Kelly J., and Arvanitakis Z. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging 27 2 (2006) 252-261
303. Schroder J.M. Ferritinopathy: diagnosis by muscle or nerve biopsy, with a note on other nuclear inclusion body diseases. Acta Neuropathol. (Berl.) 109 1 (2005) 109-114
304. Sekyere E.O., and Richardson D.R. The membrane-bound transferrin homologue melanotransferrin: roles other than iron transport?. FEBS Lett. 483 (2000) 11-16
305. Sekyere E.O., Dunn L.L., and Richardson D.R. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochim. Biophys. Acta 1722 2 (2005) 131-142
306. Sekyere E.O., Dunn L.L., Rahmanto Y.S., and Richardson D.R. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood 107 (2006) 2599-2601
307. Senior K. New genes reveal major role for iron in neurodegeneration. Lancet 358 (2001) 302
308. Shachar D.B., Kahana N., Kampel V., Warshawsky A., and Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46 2 (2004) 254-263
309. Shamoto-Nagai1 M., Maruyama1 W., Yi H., Akao Y., Tribl F., Gerlach M., Osawa T., Riederer P., and Naoi M. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J. Neural Transm. 113 (2006) 633-644
310. Shevell M. Hallervorden and history. N. Engl. J. Med. 348 1 (2003) 3-4
311. Shih A.Y., Fernandes H.B., Choi F.Y., Kozoriz M.G., Liu Y., Li P., Cowan C.M., and Klegeris A. Policing the police: astrocytes modulate microglial activation. J. Neurosci. 26 15 (2006) 3887-3888
312. Siddappa A.J., Rao R.B., Wobken J.D., Casperson K., Leibold E.A., Connor J.R., and Georgieff M.K. Iron deficiency alters iron regulatory protein and iron transport protein expression in the perinatal rat brain. Pediatr. Res. 53 5 (2003) 800-807
313. Smith M.A., Wehr K., Harris P.L., Siedlak S.L., Connor J.R., and Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 788 (1998) 232-236
314. Smith S.R., Cooperman S., Lavaute T., Tresser N., Ghosh M., Meyron-Holtz E., Land W., Ollivierre H., Jortner B., Switzer III R., Messing A., and Rouault T.A. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann. N. Y. Acad. Sci. 1012 (2004) 65-83
315. Snowdon D.A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139 5 Pt 2 (2003) 450-454
316. Song W., Su H., Song S., Paudel H.K., and Schipper H.M. Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J. Cell Physiol. 206 3 (2006) 655-663
317. Swaiman K.F. Hallervorden-Spatz syndrome and brain iron metabolism. Arch. Neurol. 48 (1991) 1285-1293
318. Swaiman K.F. Hallervorden-Spatz syndrome. Pediatr. Neurol. 25 (2001) 102-108
319. Takahashi M., Dore S., Ferris C.D., Tomita T., Sawa A., Wolosker H., Borchelt D.R., Iwatsubo T., Kim S.H., Thinakaran G., Sisodia S.S., and Snyder S.H. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 28 2 (2000) 461-473
320. Takahashi Y., Miyajima H., Shirabe S., Nagataki S., Suenaga A., and Gitlin J.D. Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Hum. Mol. Genet. 5 (1996) 81-84
321. Takeuchi Y., Yoshikawa M., Tsujino T., Kohno S., Tsukamoto N., Shiroi A., Kikuchi E., Fukui H., and Miyajima H. A case of aceruloplasminaemia: abnormal serum ceruloplasmin protein without ferroxidase activity. J. Neurol. Neurosurg. Psychiatry 72 4 (2002) 543-545
322. Talukder M.J., Takeuchi T., and Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J. Vet. Med. Sci. 65 9 (2003) 957-964
323. Tandy S., Williams M., Leggett A., Lopez-Jimenez M., Dedes M., Ramesh B., Srai S.K., and Sharp P. Nramp2 expression is associated with pH-dependent iron uptake across the apical membrane of human intestinal Caco-2 cells. J. Biol. Chem. 275 (2000) 1023-1029
324. 2+-initiated lipid peroxidation in liposomes: Dual function of ferrous iron, role of the pre-existed peroxides and lipid peroxl radical. Biochem J. 352 2 (2000) 27-36
325. Tenhunen R., Marver H.S., and Schmid R. Microsomal heme oxygenase, Characterization of the enzyme. J. Biol. Chem. 244 (1969) 6388-6394
326. Thomas M., Hayflick S.J., and Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov. Disord. 19 1 (2004) 36-42
327. Thomas M., and Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr. Opin. Neurol. 17 (2004) 437-442
328. Thompson K.J., Shoham S., and Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 55 (2001) 155-164
329. Tofaris G.K., Revesz T., Jacques T.S., Papacostas S., and Chataway J. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch. Neurol. 64 2 (2007) 280-282
330. Torsdottir G., Kristinsson J., Sveinbjornsdottir S., Snaedal J., and Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol. Toxicol. 85 (1999) 239-243
331. Touret N., Furuya W., Forbes J., Gros P., and Grinstein S. Dynamic traffic through the recycling compartment couples the metal transporter Nramp2 (DMT1) with the transferrin receptor. J. Biol. Chem. 278 28 (2003) 25548-25557
332. Trinder D., Oates P.S., Thomas C., Sadleir J., and Morgan E.H. Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut 46 (2000) 270-276
333. Ueda F., Raja K.B., Simpson R.J., Trowbridge I.S., and Bradbury M.W. Rate of 59Fe uptake into brain and cerebrospinal fluid and the influence thereon of antibodies against the transferrin receptor. J. Neurochem. 60 (1993) 106-113
334. Ujiie M., Dickstein D.L., and Jefferies W.A. p97 as a biomarker for Alzheimer disease. Front Biosci. 7 (2002) e42-e47
335. VanLandingham J.W., and Levenson C.W. Effect of retinoic acid on ferritin H expression during brain development and neuronal differentiation. Nutr. Neurosci. 6 1 (2003) 39-45
336. Vargas J.D., Herpers B., McKie A.T., Gledhill S., McDonnell J., van den Heuvel M., Davies K.E., and Ponting C.P. Stromal cell-derived receptor 2 and cytochrome b-561 are functional ferric reductases. Biochim. Biophys. Acta 1651 (2003) 116-123
337. Vassiliev V., Harris Z.L., and Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res. Rev. 49 (2005) 633-640
338. Vidal R., Ghetti B., Takao M., Brefel-Courbon C., Uro-Coste E., Glazier B.S., Siani V., Benson M.D., Calvas P., Miravalle L., Rascol O., and Delisle M.B. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63 4 (2004) 363-380
339. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., Gitschier J., Anderson G.J., and Hephaestin. A ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21 (1999) 195-199
340. Wang X.S., Ong W.Y., and Connor J.R. A light and electron microscopic study of the iron transporter protein DMT-1 in the monkey cerebral neocortex and hippocampus. J. Neurocytol. 30 (2001) 353-360
341. Wang X., Li G.J., and Zheng W. Upregulation of DMT1 expression in choroidal epithelia of the blood-CSF barrier following manganese exposure in vitro. Brain Res. 1097 1 (2006) 1-10
342. Wardrop S.L., and Richardson D.R. The effect of intracellular iron concentration and nitrogen monoxide on NRAMP2 expression and non-transferrin-bound iron uptake. Eur. J. Biochem. 263 (1999) 41-49
343. Wardrop S.L., and Richardson D.R. Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages. Eur. J. Biochem. 267 22 (2000) 6586-6593
344. Wu L., and Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57 4 (2005) 585-630
345. Wu L.J., Leenders A.G., Cooperman S., Meyron-Holtz E., Smith S., Land W., Tsai R.Y., Berger U.V., Sheng Z.H., and Rouault T.A. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res. 1001 (2004) 108-117
346. Xie J.X., Tsoi Y.K., Chang Y.Z., Ke Y., and Qian Z.M. Effects of ferroxidase activity and species on ceruloplasmin mediated iron uptake by BT325 cells. Brain Res. Mol. Brain Res. 99 (2002) 12-16
347. Xie J.X., Jiang H., Chen W.F., and Qian Z.M. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Experim. Neurol. 182 (2003) 483-489
348. Yamada T., Tsujioka Y., Taguchi J., Takahashi M., Tsuboi Y., Moroo I., Yang J., and Jefferies W.A. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease. Brain Res. 845 (1999) 1-5
349. Yamada Y., Amagasaki T., Jacobsen D.W., and Green R. Lactoferrin binding by leukemia cell lines. Blood 70 (1987) 264-270
350. Yamanaka K., Minato N., and Iwai K. Stabilization of iron regulatory protein 2, IRP2, by aluminum. FEBS Lett. 462 (1999) 216-220
351. Yamashita S., Maeda Y., Ohmori H., Uchida Y., Hirano T., Yonemura K., Uyama E., and Uchino M. Pantothenate kinase-associated neurodegeneration initially presenting as postural tremor alone in a Japanese family with homozygous N245S substitutions in the pantothenate kinase gene. J. Neurol. Sci. 225 1-2 (2004) 129-133
352. Yeh K.Y., Yeh M., Watkins J.A., Rodriguez-Paris J., and Glass J. Dietary iron induces rapid changes in rat intestinal divalent metal transporter expression. Am J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G1070-G1079
353. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., Hiyamuta S., Ikeda S., Shimizu N., and Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9 (1995) 267-272
354. Yoshida K., Kaneko K., Miyajima H., Tokuda T., Nakamura A., Kato M., and Ikeda S. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J. Neurol. Sci. 175 (2000) 91-95
355. Youdim M.B., Stephenson G., and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 1012 (2004) 306-325
356. Young S.P., Fahmy M., and Golding S. Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. FEBS Lett. 411 (1997) 93-96
357. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., and Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 6 (2001) 1766-1773
358. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., Giaveri G., Arosio P., Santambrogio P., Fariello R.G., Karatekin E., Kleinman M.H., Turro N., Hornykiewicz O., and Zucca F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U.S.A. 101 26 (2004) 9843-9848
359. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 (2004) 863-873
360. Zhang Y.M., Rock C.O., and Jackowski S. Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration. J. Biol. Chem. 281 1 (2006) 107-114
361. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., and Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 28 (2001) 345-349
362. Zucca F.A., Bellei C., Giannelli S., Terreni M.R., Gallorini M., Rizzio E., Pezzoli G., Albertini A., and Zecca L. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J. Neural Transm. 113 (2006) 757-767